Financial Data and Key Metrics Changes - The company exceeded expectations for the quarter and is confident in achieving at least $16 of EPS for the full year [11][12] - The adjusted operating cost ratio is expected to decrease by 30 basis points for the year [22] Business Line Data and Key Metrics Changes - Individual Medicare Advantage (MA) membership growth is anticipated to be around 5% year-over-year, with significant gains made throughout 2024 [14][15] - Medical costs in Q3 were largely in line with expectations, with successful cost control efforts noted in areas like value-based care contracts [20][21] Market Data and Key Metrics Changes - The company expects industry growth of 5% to 5.5% for the coming year, down from approximately 6% in the current year [65][66] - The company anticipates a loss of a few hundred thousand members in 2025, which is considered reasonable [43] Company Strategy and Development Direction - The company is focused on delivering a disciplined Medicare product experience, operating with clinical excellence, managing an efficient back office, and deploying growth capital effectively [9][10] - Investments are being made to improve STARS ratings and overall operational performance, with a target for an Investor Day in May 2025 to provide further clarity on long-term strategies [13][27] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the need for improvement in STARS ratings and is making investments to close gaps in care [17][18] - The company remains optimistic about the positive outlook for Medicare Advantage and value-based care [27] Other Important Information - The company has been recognized as the number one health insurer for customer experience by Forrester for four consecutive years [16] - The company is implementing AI solutions to enhance operational efficiency, particularly in care management [22][23] Q&A Session Summary Question: Investment spending for 2025 - Management indicated that while they are planning for margin improvement in MA, they are also balancing investment spending, which could be around $500 million [28][30] Question: MLR results and 2025 bids - Management confirmed that current year claims developed as expected, and they feel confident about their pricing assumptions for 2025 [40][42] Question: STARS recovery and margin targets - Management stated that meaningful STARS progression is necessary to achieve the 3% margin target by 2027, but they did not specify a minimum level required [46][48] Question: Specialty drug costs - Management noted that higher specialty drug costs are primarily due to new treatments and label expansions, not significantly impacted by IRA changes [50][52] Question: Retention strategies - The company is enhancing digital tools and support for brokers to improve member retention amid plan exits [67][68] Question: Inpatient claims denial rates - Management reported stable trends in inpatient claims denial rates since implementing new rules, with no significant variations noted [86][90] Question: 2026 rates expectations - Management expressed cautious optimism regarding 2026 rates, anticipating adjustments based on observed trends [119]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

For the quarter ended September 2024, Humana (HUM) reported revenue of $29.3 billion, up 14.8% over the same period last year. EPS came in at $4.16, compared to $7.78 in the year-ago quarter.The reported revenue represents a surprise of +2.24% over the Zacks Consensus Estimate of $28.66 billion. With the consensus EPS estimate being $3.48, the EPS surprise was +19.54%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Humana (HUM) came out with quarterly earnings of $4.16 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $7.78 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 19.54%. A quarter ago, it was expected that this health insurer would post earnings of $5.89 per share when it actually produced earnings of $6.96, delivering a surprise of 18.17%. Over the last four quarters, the company ha ...

n e w s r e l e a s e Exhibit 99.2 Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY 40202 http://www.humana.com FOR MORE INFORMATION CONTACT: Lisa Stoner Humana Investor Relations (502) 580-2652 e-mail: LStamper@humana.com Mark Taylor Humana Corporate Communications (317) 753-0345 e-mail: MTaylor108@humana.com Humana Reports Third Quarter 2024 Financial Results; Updates Full Year Adjusted 2024 Financial Guidance • Reports 3Q24 earnings per share (EPS) of $3.98 on a GAAP basis, Adjusted EPS of $ ...

Humana Inc. (HUM) is slated to release third-quarter 2024 results on Oct. 30, before the opening bell. The Zacks Consensus Estimate for earnings per share is pegged at $3.48, which indicates a 55.3% plunge from the prior-year quarter's number. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. The third-quarter earnings estimate has witnessed two downward revisions over the past month. During this time, the estimate declined 1.7%. Meanwhile, the Zacks Consensus Estimate for revenues i ...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) on behalf of Humana stockholders. Our investigation concerns whether Humana has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 2, 2024, Humana disclosed that it has “approximately 1.6 million, or 2 ...

Shares of Humana Inc (NYSE:HUM) and Cigna Group (NYSE:CI) are making opposite moves today, as merger talks between the health insurance companies ramp up. According to a Bloomberg report that cited people familiar with the matter, the talks are in early stages.At last glance, HUM is 0.5% higher at $268.55. The equity is still down nearly 50% in the past 12 months, with a more than 40% year-to-date deficit to boot. Humana stock could today conquer its 20-day moving average, as it distances itself from its Oc ...

Key TakeawaysHumana shares were sharply higher in premarket trading Monday following a report that Cigna has resumed its efforts to merge with the struggling health insurer.The stock broke down below a descending channel late last month, but promptly reversed course the following week to reclaim the pattern's lower trendline, potentially indicating a bear trap.Investors should watch key overhead levels on Humana's chart around $300, $370 and $450, while also watching a crucial area of support near $230. Hum ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. ("Humana" or "the Company") (NYSE: HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUM. Investigation Details On October 2, 2024, Humana disclosed that it has "approximately 1.6 million, or 25%, of its members currently ...